Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Issued Additional Nasdaq Delisting Warning

NEW YORK, May 29 (GenomeWeb News) - Sequenom said last week that it has received a letter from the Nasdaq exchange notifying the company that it is currently out of compliance with the stockholder equity listing requirement.


According to Sequenom, the letter indicates that the company's stockholders' equity of $8,329,000 as of March 31 is less than the $10,000,000 requirement.


Last month, Sequenom reported that it had failed to meet the Nasdaq's minimum closing bid price requirement, and that it had until June 15 to regain compliance before its shares would be delisted from the exchange.


Sequenom said that the stockholders' equity issue could serve as an additional basis for delisting.


The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.